With the onset of targeted therapies, clinical trials such as coBRIM or COLUMBUS revealed the efficacy of specialized BRAF inhibitors in cases of BRAF exon 15 p.V600-mutant melanomas [44,45]. This evidence concerns the gene BRAF and melanoma.